5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
Authors:
Open Access
- 1 February 1989
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 59 (2) , 287-290
Abstract
This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the benefit of such data for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89 patients (group 1; 228 cycles) revealed that both the time-concentration product (AUC) for the entire cycle and the half-cycle AUC (AUC0-3 days) were predictive of cycle toxicity. Real-time analysis of individual AUC0-3 days was used to decide whether to reduce the dose during the second half of the cycle for a total of 249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2 courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0.05) and a statistically significant reduction was observed in the incidence of toxic cycles (greater than grade 2, group 1 = 20% versus group 2 = 12.4%; 0.02 less than P less than 0.05). Pharmacokinetic follow-up of these patients has proved to be an objective means to improve therapeutic index significantly.Keywords
This publication has 15 references indexed in Scilit:
- Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancerCancer, 1987
- Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancerCancer Chemotherapy and Pharmacology, 1986
- Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.Journal of Clinical Oncology, 1985
- A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.Journal of Clinical Oncology, 1985
- Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatinCancer, 1985
- Pharmacokinetic Principles of Antineoplastic Drug TherapyThe Journal of Clinical Pharmacology, 1983
- CLINICAL-TRIAL OF CISPLATIN AND 5-FU INFUSION AS INITIAL TREATMENT FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK1982
- The pharmacology of the fluoropyrimidines.Pharmacological Reviews, 1981
- Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.Clinical Chemistry, 1979
- Neurotoxicity of Commonly Used Antineoplastic AgentsNew England Journal of Medicine, 1974